McKenna Sarah, Eatock Martin
Department of Oncology, Belfast City Hospital, Belfast, Northern Ireland.
Oncologist. 2003;8(2):149-60. doi: 10.1634/theoncologist.8-2-149.
Pancreatic carcinoma is a commonly occurring cancer that tends to present late in its course when potentially curative surgical treatment is not possible. The majority of patients are, therefore, candidates for systemic therapy. We review the patient and disease-related factors that contribute to the difficulties in the medical management of this condition and discuss new methods of assessing response to treatment, including the introduction of more clinically relevant novel end points such as clinical benefit response. We review the current trial literature examining the use of conventional cytotoxic agents in this disease, both as single agents and in combination. We also review the use of more novel targeted agents and examine their potential utility in this disease. The use of the farnesyl transferase inhibitors, matrix metalloproteinase inhibitors, epidermal growth factor receptor antagonists, and angiogenesis inhibitors is discussed.
胰腺癌是一种常见的癌症，往往在病程晚期才出现，此时可能无法进行根治性手术治疗。因此，大多数患者适合接受全身治疗。我们回顾了导致这种疾病医疗管理困难的患者和疾病相关因素，并讨论了评估治疗反应的新方法，包括引入更具临床相关性的新终点，如临床获益反应。我们回顾了目前研究常规细胞毒性药物在这种疾病中作为单药和联合用药的试验文献。我们还回顾了更多新型靶向药物的使用，并研究了它们在这种疾病中的潜在效用。讨论了法尼基转移酶抑制剂、基质金属蛋白酶抑制剂、表皮生长因子受体拮抗剂和血管生成抑制剂的使用。
